Evotec (EVO) Competitors $3.67 -0.08 (-2.13%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$3.61 -0.06 (-1.66%) As of 05:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVO vs. PTCT, MENS, ACLX, PCVX, KRYS, ARWR, ACAD, ADMA, AAPG, and MTSRShould you be buying Evotec stock or one of its competitors? The main competitors of Evotec include PTC Therapeutics (PTCT), Jyong Biotech (MENS), Arcellx (ACLX), Vaxcyte (PCVX), Krystal Biotech (KRYS), Arrowhead Pharmaceuticals (ARWR), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), Ascentage Pharma Group International (AAPG), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry. Evotec vs. Its Competitors PTC Therapeutics Jyong Biotech Arcellx Vaxcyte Krystal Biotech Arrowhead Pharmaceuticals ACADIA Pharmaceuticals ADMA Biologics Ascentage Pharma Group International Metsera PTC Therapeutics (NASDAQ:PTCT) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment. Do institutionals & insiders have more ownership in PTCT or EVO? 5.8% of Evotec shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor PTCT or EVO? In the previous week, PTC Therapeutics had 3 more articles in the media than Evotec. MarketBeat recorded 6 mentions for PTC Therapeutics and 3 mentions for Evotec. PTC Therapeutics' average media sentiment score of 1.27 beat Evotec's score of 0.88 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend PTCT or EVO? PTC Therapeutics currently has a consensus price target of $69.00, suggesting a potential upside of 13.94%. Evotec has a consensus price target of $5.40, suggesting a potential upside of 47.14%. Given Evotec's higher probable upside, analysts plainly believe Evotec is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.53Evotec 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk and volatility, PTCT or EVO? PTC Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500. Is PTCT or EVO more profitable? PTC Therapeutics has a net margin of 35.65% compared to Evotec's net margin of -20.14%. Evotec's return on equity of -16.94% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics35.65% -106.31% 30.61% Evotec -20.14%-16.94%-8.14% Which has preferable valuation & earnings, PTCT or EVO? Evotec has higher revenue and earnings than PTC Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M5.96-$363.30M$6.978.69Evotec$862.40M1.51-$212.18MN/AN/A SummaryPTC Therapeutics beats Evotec on 8 of the 14 factors compared between the two stocks. Get Evotec News Delivered to You Automatically Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVO vs. The Competition Export to ExcelMetricEvotecMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.33B$2.55B$5.76B$10.50BDividend YieldN/A53.63%5.53%4.57%P/E RatioN/A23.4075.9626.62Price / Sales1.51513.39473.7891.77Price / CashN/A171.0137.4661.85Price / Book1.265.3813.486.45Net Income-$212.18M$32.95M$3.29B$271.57M7 Day Performance0.82%3.00%1.83%2.61%1 Month Performance0.82%4.89%4.00%7.28%1 Year Performance9.55%0.71%75.89%29.60% Evotec Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOEvotec1.7496 of 5 stars$3.67-2.1%$5.40+47.1%+12.2%$1.33B$862.40M0.004,827News CoverageGap DownPTCTPTC Therapeutics3.8011 of 5 stars$58.98-3.5%$69.00+17.0%+64.8%$4.85B$806.78M8.461,410Positive NewsMENSJyong BiotechN/A$51.82-15.7%N/AN/A$4.68BN/A0.0031High Trading VolumeACLXArcellx2.3083 of 5 stars$75.20-1.3%$114.31+52.0%-7.9%$4.23B$107.94M-21.9980Positive NewsPCVXVaxcyte2.0796 of 5 stars$31.00-3.6%$106.25+242.7%-70.4%$4.18BN/A-7.54160Positive NewsKRYSKrystal Biotech4.9356 of 5 stars$155.71+8.4%$209.00+34.2%-8.4%$4.16B$359.21M31.65210High Trading VolumeARWRArrowhead Pharmaceuticals4.217 of 5 stars$28.67-3.5%$43.14+50.5%+62.5%$4.11B$3.55M-22.40400ACADACADIA Pharmaceuticals4.3946 of 5 stars$24.67+4.5%$29.65+20.2%+44.9%$3.98B$957.80M18.55510ADMAADMA Biologics3.3084 of 5 stars$15.30-5.0%$27.67+80.8%-20.2%$3.84B$426.45M17.79530Positive NewsAAPGAscentage Pharma Group InternationalN/A$38.63-4.5%N/AN/A$3.77B$134.35M0.00600MTSRMetseraN/A$34.21-4.1%$63.50+85.6%N/A$3.75BN/A0.0081Trending NewsAnalyst Downgrade Related Companies and Tools Related Companies PTC Therapeutics Alternatives Jyong Biotech Alternatives Arcellx Alternatives Vaxcyte Alternatives Krystal Biotech Alternatives Arrowhead Pharmaceuticals Alternatives ACADIA Pharmaceuticals Alternatives ADMA Biologics Alternatives Ascentage Pharma Group International Alternatives Metsera Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVO) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVO Stock Alerts